Patexia Logo
Patexia Logo
Products
  • IP Intelligence Reports
  • Patexia Concierge
  • Patent Analyzer
  • Trademarks Analyzer
  • Litigation Analyzer
  • All Products
Services
  • Lateral Opportunities
  • Expert Witness
  • Research Studies
  • Strategic Partnership
  • All Services
IP Community
  • IP Community
  • IP Webinars
  • In the News
Company
  • About Us
  • Press Release
  • Careers
  • Contact Us
Login
JoinBook a Meeting
Patexia Logo
Products
  • IP Intelligence Reports
  • Patexia Concierge
  • Patent Analyzer
  • Trademarks Analyzer
  • Litigation Analyzer
Services
  • Lateral Opportunities
  • Expert Witness
  • Research Studies
  • Strategic Partnership
Company
  • About Us
  • Press Release
  • Careers
  • Contact Us
Resources
  • IP Community
  • IP Webinars
  • In the News
Contact
  • (310) 909-7611
  • 100 Wilshire Blvd. Suite 700
    Santa Monica, CA 90401 USA
  • info@patexia.com
  • Send a message
Follow Us
Terms and Conditions|Privacy Policy
© 2010-2023 Patexia Inc. All Rights Reserved.
All Articles
Pedram Sameni
4 days ago
•
Lateral Moves
CAFC Litigation
Patexia Insight 195: Lateral Moves of CAFC Attorneys in 2023
  In late October, we unveiled the CAFC Intelligence Report 2023, a comprehensive analysis encompassing stakeholders before the Court of... Read More
Mikele Bicolli
Dec 5, 2023
•
Featured
CAFC Litigation
US Appeals Court Vacates Record Patent Damages Against Intel in Landmark Ruling
  The legal battle between chipmaker Intel Corporation and patent holding company VLSI has taken another turn as the US... Read More
Nika Aldrich
Dec 5, 2023
•
Featured
CAFC Litigation
Fresh From the Bench: Latest Precedential Patent Case
CASE OF THE WEEK Penumbra, Inc. v. Rapidpulse, Inc., IPR2021-01466, Paper 34 (P.T.A.B. March 10, 2023) In a PTAB decision... Read More
Knobbe Martens
Dec 5, 2023
•
Featured
ANDA Litigation
The Federal Trade Commission Put Brand Drug Manufacturers on Notice About Improperly Listing Patents in the Orange Book and Then Followed Through With More Than 100 Patent Challenges
Written by: Susan M. Janicki, Ph.D. & Agnes Juang, Ph.D. The Federal Trade Commission (FTC) issued a policy statement[1] on September... Read More
Knobbe Martens
Dec 4, 2023
•
Featured
ANDA Litigation
Recent Developments in Medical Casts
Written by: Alexander D. Zeng & Philip M. Nelson On October 5, 2023, the World Intellectual Property Organization published Cast21’s PCT application related to... Read More
Pedram Sameni
Nov 30, 2023
•
Featured
PTAB Litigation
Lateral Moves
Patexia Insight 194: The Top Lateral Moves of PTAB Attorneys in 2023
The Patent Trial and Appeal Board (PTAB) holds a pivotal position within intellectual property law, wielding substantial influence over patent... Read More
  • <
  • 1
  • 2
  • ...
  • 1642
  • >
The First FDA Approved, Chinese Developed, PD-1 Inhibitor For Nasopharyngeal Carcinoma
Knobbe Martens
Nov 29, 2023
•
ANDA Litigation
The First FDA Approved, Chinese Developed, PD-1 Inhibitor For Nasopharyngeal Carcinoma
Written by:&nbsp;Jason J. Jardine On October 27th, 2023, the U.S. Food and Drug Administration (FDA) approved LOQTORZITM (toripalimab-tpzi), developed by Coherus... Read More
US Appeals Court Vacates Record Patent Damages Against Intel in Landmark Ruling
Mikele Bicolli
Dec 5, 2023
•
CAFC Litigation
US Appeals Court Vacates Record Patent Damages Against Intel in Landmark Ruling
&nbsp; The legal battle between chipmaker Intel Corporation and patent holding company VLSI has taken another turn as the US Court... Read More
Fresh From the Bench: Latest Precedential Patent Case
Nika Aldrich
Dec 5, 2023
•
CAFC Litigation
Fresh From the Bench: Latest Precedential Patent Case
CASE OF THE WEEK Penumbra, Inc. v. Rapidpulse, Inc., IPR2021-01466, Paper 34 (P.T.A.B. March 10, 2023) In a PTAB decision that was... Read More
The Federal Trade Commission Put Brand Drug Manufacturers on Notice About Improperly Listing Patents in the Orange Book and Then Followed Through With More Than 100 Patent Challenges
Knobbe Martens
Dec 5, 2023
•
ANDA Litigation
The Federal Trade Commission Put Brand Drug Manufacturers on Notice About Improperly Listing Patents in the Orange Book and Then Followed Through With More Than 100 Patent Challenges
Written by:&nbsp;Susan M. Janicki, Ph.D. &amp; Agnes Juang, Ph.D. The Federal Trade Commission (FTC) issued a policy statement[1] on September 14,... Read More
Recent Developments in Medical Casts
Knobbe Martens
Dec 4, 2023
•
ANDA Litigation
Recent Developments in Medical Casts
Written by:&nbsp;Alexander D. Zeng &amp; Philip M. Nelson On&nbsp;October 5, 2023, the World Intellectual Property Organization published&nbsp;Cast21&rsquo;s&nbsp;PCT application related to its... Read More
Patexia Insight 194: The Top Lateral Moves of PTAB Attorneys in 2023
Pedram Sameni
Nov 30, 2023
•
PTAB Litigation
Lateral Moves
Patexia Insight 194: The Top Lateral Moves of PTAB Attorneys in 2023
The Patent Trial and Appeal Board (PTAB) holds a pivotal position within intellectual property law, wielding substantial influence over patent... Read More
The First FDA Approved, Chinese Developed, PD-1 Inhibitor For Nasopharyngeal Carcinoma
Knobbe Martens
Nov 29, 2023
•
ANDA Litigation
The First FDA Approved, Chinese Developed, PD-1 Inhibitor For Nasopharyngeal Carcinoma
Written by:&nbsp;Jason J. Jardine On October 27th, 2023, the U.S. Food and Drug Administration (FDA) approved LOQTORZITM (toripalimab-tpzi), developed by Coherus... Read More
US Appeals Court Vacates Record Patent Damages Against Intel in Landmark Ruling
Mikele Bicolli
Dec 5, 2023
•
CAFC Litigation
US Appeals Court Vacates Record Patent Damages Against Intel in Landmark Ruling
&nbsp; The legal battle between chipmaker Intel Corporation and patent holding company VLSI has taken another turn as the US Court... Read More
Fresh From the Bench: Latest Precedential Patent Case
Nika Aldrich
Dec 5, 2023
•
CAFC Litigation
Fresh From the Bench: Latest Precedential Patent Case
CASE OF THE WEEK Penumbra, Inc. v. Rapidpulse, Inc., IPR2021-01466, Paper 34 (P.T.A.B. March 10, 2023) In a PTAB decision that was... Read More
The Federal Trade Commission Put Brand Drug Manufacturers on Notice About Improperly Listing Patents in the Orange Book and Then Followed Through With More Than 100 Patent Challenges
Knobbe Martens
Dec 5, 2023
•
ANDA Litigation
The Federal Trade Commission Put Brand Drug Manufacturers on Notice About Improperly Listing Patents in the Orange Book and Then Followed Through With More Than 100 Patent Challenges
Written by:&nbsp;Susan M. Janicki, Ph.D. &amp; Agnes Juang, Ph.D. The Federal Trade Commission (FTC) issued a policy statement[1] on September 14,... Read More
Recent Developments in Medical Casts
Knobbe Martens
Dec 4, 2023
•
ANDA Litigation
Recent Developments in Medical Casts
Written by:&nbsp;Alexander D. Zeng &amp; Philip M. Nelson On&nbsp;October 5, 2023, the World Intellectual Property Organization published&nbsp;Cast21&rsquo;s&nbsp;PCT application related to its... Read More
Patexia Insight 194: The Top Lateral Moves of PTAB Attorneys in 2023
Pedram Sameni
Nov 30, 2023
•
PTAB Litigation
Lateral Moves
Patexia Insight 194: The Top Lateral Moves of PTAB Attorneys in 2023
The Patent Trial and Appeal Board (PTAB) holds a pivotal position within intellectual property law, wielding substantial influence over patent... Read More
The First FDA Approved, Chinese Developed, PD-1 Inhibitor For Nasopharyngeal Carcinoma
Knobbe Martens
Nov 29, 2023
•
ANDA Litigation
The First FDA Approved, Chinese Developed, PD-1 Inhibitor For Nasopharyngeal Carcinoma
Written by:&nbsp;Jason J. Jardine On October 27th, 2023, the U.S. Food and Drug Administration (FDA) approved LOQTORZITM (toripalimab-tpzi), developed by Coherus... Read More
Featured